Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?

xlomafota13 shared this article with you from Inoreader Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients? Via Association française pour l'étude du cancer Bull Cancer. 2021 May 19:S0007-4551(21)00166-1. doi: 10.1016/j.bulcan.2021.03.011. Online ahead of print. ABSTRACT Hairy cell leukemia is a rare form of leukemia: three hundred new cases are diagnosed each year in France. The diagnosis is based on: (1) morphological examination of the blood and bone marrow smear, (2) analysis by flow cytometry of hairy cells, which express three or the four following markers: CD11c, CD25, CD103 and CD123, (3) identification of the BRAFV600E mutation, a true molecular marker of the disease. The management of treatment has evolved considerably in recent years. As of today, the purine analogues remain the standard treatment in the first line. Relapses are however observed in about 40% of cases. In the event of a first relapse, the preferred option is treatment with immunochemotherapy i.e. a combination of cladribine plus rituximab. Subsequent relapses are treated with moxetumomab pasudotox or B RAF inhibitors which provide indisputable benefits if third-line treatment is required. We will discuss in patients with relapsed/refractory hairy cell leukemia the needs for personalized medicine and the advantages and disadvantages of each treatment modality. The good prognosis for LT requires treatments that are not immunosuppressive, non-myelotoxic, and do not increase the risk of secondary cancers. PMID:34023063 | DOI:10.1016/j.bulcan.2021.03.011 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.